Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brett Atwater

Clinical Cardiac Electrophysiology Fairfax, VA Medical Doctor

NPI 1053376194 CMS profile 678274

8081 Innovation Park Dr Ste 602, Ste 602, Fairfax, VA 22031

Open in the dashboard

General payments

$319,420

496 records reported · program years 2019–2025

Research payments

$26,838

Paid to them · 16 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$841,463 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Brett Atwater of Fairfax, VA is reported in the CMS Open Payments database as having received $319,420 across 496 general payments and $26,838 in research payments paid to them. Separately, studies naming them as principal investigator received $841,463 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $113,218 134
2025 Research $2,600 4
2024 General $69,367 85
2024 Research $23,238 10
2023 General $66,049 114
2022 General $14,408 36
2021 General $8,330 20
2020 General $11,618 17
2020 Research $1,000 2
2019 General $36,428 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brett Atwater
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Brett Atwater were reported at $113,218. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Brett Atwater Clinical Cardiac Electrophysiology median Middle half National median
2019 $36,428 $2,361 $585–$8,260 $163
2020 $11,618 $993 $247–$4,351 $114
2021 $8,330 $1,185 $326–$4,739 $132
2022 $14,408 $2,073 $554–$6,789 $149
2023 $66,049 $2,568 $759–$8,159 $160
2024 $69,367 $2,557 $703–$7,403 $164
2025 $113,218 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $145,030 208 payments
  2. Biosense Webster, Inc. $41,363 63 payments
  3. Abbott Laboratories $40,234 87 payments
  4. Medtronic Vascular, Inc. $23,864 53 payments
  5. Boston Scientific Corporation $17,279 23 payments
  6. Pfizer Inc. $14,600 5 payments
  7. E.R. Squibb & Sons, L.L.C. $14,180 3 payments
  8. Biotronik Inc. $13,074 31 payments
  9. Medical Device Business Services, Inc. $8,648 5 payments
  10. Volta Medical Inc $320 2 payments
  11. Other $829 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $131,294 38 payments
  2. Consulting Fee $121,400 63 payments
  3. Travel and Lodging $44,206 153 payments
  4. Food and Beverage $17,224 239 payments
  5. Honoraria $5,200 1 payment
  6. Education $96 2 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $47,211 56 payments
  2. Micra $25,491 43 payments
  3. ELIQUIS Cardiovascular;Metabolic Disease $14,600 5 payments
  4. AVEIR $13,534 27 payments
  5. ELIQUIS Cardiovascular $8,000 1 payment
  6. ACCENT $6,975 5 payments
  7. TACTICATH ABLATION CATHETER, SENSOR ENABLED $5,529 2 payments
  8. Carto 3 System $4,629 10 payments
  9. AFFERA MAPPING SYSTEM $3,713 8 payments
  10. General - Therapies $3,071 4 payments
  11. Other $22,987 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $25,838 14 payments
  2. Medtronic Vascular, Inc. $1,000 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

92

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$52,972

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

54.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 29 $29,898
Multaq Dronedarone Hcl Brand 21 $21,744
Amiodarone Hcl Generic 13 $955
Metoprolol Succinate Generic 29 $375

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$147,389

Medicare's payments for the services billed

Medicare patients

346

Average age 78

Services billed

1,079

148 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 51%
Heart failure 50%
Arthritis 50%
Chronic kidney disease 32%
Diabetes 31%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $7,000
$7,000 29 —
WAINUA
  • AstraZeneca Pharmaceuticals LP $54
$54 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

512 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record